TY - JOUR
T1 - Rabbit VX2 Liver Tumor Model
T2 - A Review of Clinical, Biology, Histology, and Tumor Microenvironment Characteristics
AU - Pascale, Florentina
AU - Pelage, Jean Pierre
AU - Wassef, Michel
AU - Ghegediban, Saïda H.
AU - Saint-Maurice, Jean Pierre
AU - De Baere, Thierry
AU - Denys, Alban
AU - Duran, Rafael
AU - Deschamps, Frédéric
AU - Pellerin, Olivier
AU - Maeda, Noboru
AU - Laurent, Alexandre
AU - Namur, Julien
N1 - Publisher Copyright:
Copyright © 2022 Pascale, Pelage, Wassef, Ghegediban, Saint-Maurice, De Baere, Denys, Duran, Deschamps, Pellerin, Maeda, Laurent and Namur.
PY - 2022/5/10
Y1 - 2022/5/10
N2 - The rabbit VX2 is a large animal model of cancer used for decades by interventional radiologists to demonstrate the efficacy of various locoregional treatments against liver tumors. What do we know about this tumor in the new era of targeted therapy and immune-oncology? The present paper describes the current knowledge on the clinics, biology, histopathology, and tumor microenvironment of VX2 based on a literature review of 741 publications in the liver and in other organs. It reveals the resemblance with human cancer (anatomy, vascularity, angiogenic profile, drug sensitivity, immune microenvironment), the differences (etiology, growth rate, histology), and the questions still poorly explored (serum and tissue biomarkers, genomic alterations, immune checkpoint inhibitors efficacy).
AB - The rabbit VX2 is a large animal model of cancer used for decades by interventional radiologists to demonstrate the efficacy of various locoregional treatments against liver tumors. What do we know about this tumor in the new era of targeted therapy and immune-oncology? The present paper describes the current knowledge on the clinics, biology, histopathology, and tumor microenvironment of VX2 based on a literature review of 741 publications in the liver and in other organs. It reveals the resemblance with human cancer (anatomy, vascularity, angiogenic profile, drug sensitivity, immune microenvironment), the differences (etiology, growth rate, histology), and the questions still poorly explored (serum and tissue biomarkers, genomic alterations, immune checkpoint inhibitors efficacy).
KW - angiography
KW - embolization
KW - imaging
KW - immune oncology
KW - locoregional treatments
KW - tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85130728804&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.871829
DO - 10.3389/fonc.2022.871829
M3 - Review article
AN - SCOPUS:85130728804
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 871829
ER -